← All Design Therapeutics, INC filings

Design Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
DSGN
Design Therapeutics, INC
10-K: Design Therapeutics Reports 2024 Results, Advances GeneTAC Platform
Design Therapeutics continues to advance its GeneTAC platform, focusing on treatments for inherited nucleotide repeat expansion diseases, with key clinical trials anticipated in 2025 and 2026.
NASDAQ
DSGN
Design Therapeutics, INC
10-K: Design Therapeutics Outlines Common Stock Details and Regulatory Framework in 10-K Filing
Design Therapeutics' 10-K filing details the rights and preferences of common stockholders, anti-takeover provisions, and regulatory compliance, providing a comprehensive overview of the company's governance and operational structure.